XML 14 R6.htm IDEA: XBRL DOCUMENT v3.24.0.1
STATEMENTS OF CASH FLOWS - USD ($)
$ in Thousands
 12 Months Ended
Dec. 31, 2023
Dec. 31, 2022
Cash flows used in operating activities:    
Net loss $ (13,316) $ (20,275)
Adjustments to reconcile net loss to net cash used in operating activities:    
Depreciation and amortization 628 619
Amortization of deferred financing costs and debt discount 190 389
Common stock issued for research and development 75  
Change in fair value of liability instruments   (1)
Loss on disposal of property and equipment 2  
Share-based compensation expense 569 606
Reduction in the carrying amount of operating lease right-of-use assets 117 93
Increases (decreases) in cash caused by changes in operating assets and liabilities:    
Other assets 2,397 (2,369)
Accounts payable and accrued expenses (3,677) 6,452
Change in operating lease liabilities (117) (129)
Deferred grant liability 281 1,643
Net cash used in operating activities (12,851) (12,972)
Cash flows used in investing activities:    
Purchases of property and equipment and intangible assets (160) (509)
In process research and development acquired   (250)
Net cash used in investing activities (160) (759)
Cash flows from financing activities:    
Principal payments of long-term obligations (1,608) (1,608)
Gross proceeds from sale of common stock 5,527 15,832
Payment of offering costs related to sale of common stock (348) (773)
Purchase of treasury stock (126)  
Net cash provided by financing activities 3,445 13,451
Net decrease in cash and cash equivalents (9,566) (280)
Cash and cash equivalents at beginning of period 18,120 18,400
Cash and cash equivalents at end of period 8,554 18,120
Cash paid during period for:    
Interest 222 $ 327
Supplemental schedule of non-cash investing and financing activities:    
Unpaid offering cost 174  
Common stock issued in payment for in process research and development 75  
Right-of-use assets acquired by assuming operating lease liabilities $ 71